Madison, United States
BrainXell, founded in 2015, is an industry leader in producing neurons and glia for advancements in neuroscience. With a focus on Central Nervous System (CNS) Drug Discovery, it stands out for its utilization of human iPSC-derived neurons. Spearheaded by the renowned stem cell neuroscientist, Dr. Su-Chun Zhang, the company collaborates with the University of Wisconsin–Madison’s Discovery to Product (D2P) program to transform groundbreaking research into valuable discovery tools and potential therapeutic solutions.
BrainXell offers a spectrum of high-purity, iPSC-derived human neurons aimed at bolstering drug discovery, working with major biotech and pharma entities. Headquartered in Madison, WI, and expanding in San Diego, CA through BrainXell Therapeutics, the company is pursuing innovative therapies for neurological disorders. Their lead program, BXT-110, is in the IND-enabling stages for Parkinson's disease, with additional initiatives targeting spinal cord injuries under development. This dual-location strategy strengthens their mission to bring cutting-edge therapies to market.
